Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope

Immunology

Volumn 129, Issue 3, 2010, Pages 386-395

  Marescotti, Diego ^a   Destro, Federica ^a   Baldisserotto, Anna ^b   Marastoni, Mauro ^b   Coppotelli, Giuseppe ^a   Masucci, Maria ^a   Gavioli, Riccardo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antigen processing; Cytotoxic T lymphocyte; Epstein Barr virus; Epstein Barr virus nuclear antigen 1; Gly Ala repeat

Indexed keywords

ALANINE; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON; GLYCINE; HLA A2 ANTIGEN; PROTEASOME;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL CULTURE; CELL CLONE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSOL; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOTHERAPY; LYMPHOBLASTOID CELL LINE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; VIRUS DETECTION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CELL LINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENDOPLASMIC RETICULUM; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; PEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSFECTION;

EID: 75949097473     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03190.x     Document Type: Article

References (44)

1. Schaible UE, Collins HL, Kaufmann SH. Confrontation between intracellular bacteria and the immune system. Adv Immunol 1999 71 : 267 377.
2. Zinkernagel RM. Immunology taught by viruses. Science 1996 271 : 173 178.
3. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998 16 : 323 358.
4. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999 17 : 739 779.
5. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004 5 : 670 677.
6. Masucci MG. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system. Oncogene 2004 23 : 2107 2115.
7. Kieff E, Leibowitz D. Epstein-Barr virus and its replication. In : Fields BM, Knipe DN, eds. Virology, 2nd Edn, Vol. 2. New York : Raven press, 1990 : 1889 1920.
8. Gavioli R, Kurilla MG, de Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 1993 67 : 1572 1578.
9. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992 176 : 169 176.
10. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992 176 : 157 168.
11. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997 15 : 405 431.
12. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 1996 184 : 1801 1813.
13. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997 7 : 791 802.
14. Lee SP, Brooks JM, Al-Jarrah H et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 2004 199 : 1409 1420.
15. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 2004 199 : 1421 1431.
16. + T lymphocytes. J Exp Med 2004 199 : 459 470.
17. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003 301 : 1371 1374.
18. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (London) 1995 375 : 685 688.
19. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997 94 : 12616 12621.
20. Lu J, Higashimoto Y, Appella E, Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004 172 : 4575 4582.
21. Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 2001 166 : 7063 7071.
22. Gavioli R, Guerrini R, Masucci MG, Tomatis R, Traniello S, Marastoni M. High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. FEBS Lett 1998 421 : 95 9.
23. Reali E, Guerrini R, Marastoni M, Tomatis R, Masucci MG, Traniello S, Gavioli R. A single specific amino acid residue in peptide antigens is sufficient to activate memory cytotoxic T lymphocytes: potential role of cross-reactive peptides in memory T cell maintenance. J Immunol 1999 162 : 106 113.
24. Micheletti F, Bazzaro M, Canella A, Marastoni M, Traniello S, Gavioli R. The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses. Immunology 1999 96 : 411 415.
25. Torsteinsdottir S, Masucci MG, Ehlin-Henriksson B, Brautbar C, Ben Bassat H, Klein G, Klein E. Differentiation dependent sensitivity of human B-cell derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A 1986 83 : 5620 5624.
26. Micheletti F, Guerrini R, Formentin A et al. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. Eur J Immunol 1999 29 : 2579 2589.
27. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994 152 : 163 175.
28. Neefjes JJ, Dierx J, Ploegh HL. The effect of anchor residue modifications on the stability of major histocompatibility complex class I-peptide interactions. Eur J Immunol 1993 23 : 840 845.
29. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994 180 : 1471 1483.
30. Luckey CJ, King GM, Marto JA et al. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J Immunol 1998 161 : 112 121.
31. Schwarz K, de Giuli R, Schmidtke G et al. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol 2000 164 : 6147 6157.
32. Basler M, Groettrup M. No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes. Eur J Immunol 2007 37 : 896 904.
33. Preta G, Marescotti D, Fortini C, Carcoforo P, Castelli C, Masucci M, Gavioli R. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells. Scand J Immunol 2008 68 : 579 588.
34. + T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 2000 165 : 7078 7087.
35. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997 159 : 1666 1668.
36. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997 327 : 625 635.
37. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998 8 : 84 7.
38. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 1994 91 : 664 668.
39. Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999 170 : 49 64.
40. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995 41 : 178 228.
41. + T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 2009 106 : 3318 3323.
42. + T cells that poorly kill EBV-infected cells. Viral Immunol 2002 15 : 213 225.
43. Doytchinova I, Hemsley S, Flower DR. Transporter associated with antigen processing preselection of peptides binding to the MHC: a bioinformatic evaluation. J Immunol 2004 173 : 6813 6819.
44. van Endert PM, Riganelli D, Greco G, Fleischhauer K, Sidney J, Sette A, Bach JF. The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 1995 182 : 1883 1895.